Acquisitions in Grand Est, France

Summit Partners has made a growth equity investment in Dreampath Diagnostics to accelerate the company's global expansion, scale operations and expand its product portfolio in anatomical pathology lab automation. Dreampath, headquartered in Strasbourg, France, provides patented scanners, software and consumables for sample traceability and manages more than 250 million samples across over 500 labs; financial terms were not disclosed.

Myonex has completed the acquisition of Creapharm's pharmaceutical services business, integrating Creapharm's clinical packaging, commercial packaging and bioservices into its global clinical trial supply platform. The deal brings Creapharm's cold-chain and ultra-cold capabilities and expands Myonex's service offering and European footprint; Creapharm founder Eric Placet has reinvested and joined the Myonex board.

GBA Group has acquired French contract research organization KaLy-Cell SAS, marking the group's market entry into France and expanding its European pharmaceutical network. KaLy-Cell, founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and headquartered in Plobsheim, provides hepatocyte-based in vitro contract research and safety testing services for pharmaceuticals, agrochemicals and cosmetics.

Warburg Pincus has made a major growth investment in Polyplus-transfection SA alongside existing majority shareholder ArchiMed, with both firms becoming equal shareholders while Polyplus management remains significant minority owners. The capital will be used to expand production capacity, accelerate product innovation, increase international expansion, and hire across technical, regulatory, and commercial functions to serve the gene and cell therapy market.